Analysis
We used additive genetic models with a count of variant alleles (0, 1, or 2) for each genotyped SNP or allelic dose for imputed SNPs. Cohort studies used Cox proportional hazard models to evaluate associations between SNPs and the time to incident stroke. Case-control studies used logistic regression models (additional details in the online-only Data Supplement). To control for potential population stratification, principal components of global ancestry were estimated in each study and included as covariates. Models were additionally adjusted, as appropriate, for age, sex, and site. In each study, the distribution of test statistics was reviewed using Q-Q plots to detect potential inflation because of population stratification; no large deviations were noted. We combined study-specific results in fixed effects meta-analyses with inverse variance weighting using METAL 24 ; P-value meta-analyses were also conducted. The genome-wide significance threshold was P<5×10 −8 for the GWAS discovery but we investigated all SNPs with P<10 −6 .
Validation of COMPASS Findings
Because of the absence of another large African American sample with GWAS and adjudicated stroke data, we performed a look-up of COMPASS SNPs with P<10 −6 in the METASTROKE ischemic stroke results. Given the known differences in linkage disequilibrium (LD) patterns between populations of European ancestry and African ancestry, we expanded the region of interest for each locus to include available SNPs±500 kb of the index SNPs. We applied Bonferroni correction to account for the number of loci tested.
As a secondary aim, we used COMPASS data to evaluate ischemic stroke and ischemic stroke subtype variants identified in European-ancestry populations. [6] [7] [8] [10] [11] [12] In COMPASS, we tested the reported European-ancestry GWAS SNP (ie, index SNP) as well as SNPs in moderate LD (r 2 ≥0.50) with the index SNP (±500 kb) based on HapMap CEU to capture more broadly the European-ancestry index signal. Again, we applied a Bonferroni-corrected significance threshold.
Power
Using Quanto (v1.2.4), 25 we estimated reasonable power (≥80%) to detect low frequency common variants (0.09≥minor allele frequency≤0.15) associated with ≥50% increased (or decreased) risk of stroke in our discovery aim. As minor allele frequency increased to 0.50, we had reasonable power to detect increasingly smaller SNPstroke associations, down to ≈25% increased (or decreased) risk (ie, effect size≈±0. 22-0.29) . Power to detect rarer variants, or common variants with more modest associations, was limited. 26 
Results

Discovery of Stroke-Associated Loci
COMPASS comprises 14 745 African Americans, including 1365 ischemic and 1592 total stroke cases ( Table I in −7 ]. An additional 18 SNPs had suggestive evidence of association (P<1×10 −6 ; Table II in the online-only Data Supplement). Five were for ischemic stroke-including PTPRG, CDC5L, and HPS4-ASPHD2 loci SNPs and 1 intergenic SNP (chr14q31)-and 15 SNPs were for total strokeincluding SNPs in the PTPRG, HDAC9, and WDFY4 loci and intergenic regions. Two SNPs, rs704341 (PTPRG/intron) and rs4471613 (15q21.3/intergenic), were suggestively associated with both ischemic and total stroke. In sensitivity analyses including only the cohort studies, associations for both SNPs remained below the P<10 −6 threshold (Table III in the onlineonly Data Supplement). associations for 5q35.2 (rs4867766; P=0.031) and 1p31.1 (rs35020936; P=0.018; Table 1 ). In 5q35.2, the intergenic SNP rs4867766 was the top SNP in both race/ethnicities, despite different minor allele frequency, 0.08 in African American and 0.21 in European-ancestry populations, whereas in 1p31.1, the top SNP differed in the populations ( Table 1) .
Testing of Ischemic Stroke GWAS Loci Identified in European-Ancestry Populations
None of the European-ancestry index SNPs were associated with ischemic stroke in African Americans at P=0.007 (P=0.05/7 loci tested; Table 2 ). When we also investigated SNPs in modest LD (Table IV in the online-only Data Supplement), we found suggestive evidence of association (P<0.05) for the PITX2, HDAC9, CDKN2A/CDKN2B, and ZFHX3 loci.
Discussion
The COMPASS collaboration represents the first large-scale GWAS meta-analysis of stroke in African Americans. We report a novel genome-wide association for total stroke at the 15q21.3 locus and report 14 additional loci suggestively associated with total or ischemic stroke in African Americans. In addition, in our African American population, we found suggestive evidence of replication for the PITX2, HDAC9, CDKN2A/CDKN2B, and ZFHX3 loci previously associated with stroke in European-ancestry populations, pointing to potential shared mechanisms for stroke susceptibility.
The top SNP, rs4471613, is located near the 3′ region of the aquaporin 9 gene (AQP9), the aldehyde dehydrogenase 1 family, member A2 (ALDH1A2), and hepatic lipase (LIPC) genes. Previous work suggests a role for AQP9 in cerebral energy metabolism as well as in brain ischemia, development of cerebral edema, and postischemic reuptake of glycerol and lactate. 27, 28 Intergenic SNPs in this region also are associated with blood lipids in populations of diverse ancestry 29 and hypertension in African Americans. 30 Although this region is mechanistically appealing, rs4471613 is in low LD with these reported SNPs. The location of rs4471613 in a H3-lysine-27-acetylation histone mark in 7 different cell types reflecting 5 tissues (ENCODE data from UCSC genome browser [https:// Two intergenic loci (5q35 and 1p31.1) identified in COMPASS were modestly associated (P<0.05) with stroke in METASTROKE. Overall, the lack of strong replication in the larger METASTROKE European-ancestry population urges caution when interpreting COMPASS associations. However, as has been reported for other phenotypes, 31 COMPASS loci could be unique to African-ancestry populations. Of note, the HDAC9 variants associated with large vessel stroke in European-ancestry populations 7, 12 are located >500 kb from the novel intronic HDAC9 variant identified in COMPASS.
Replication of stroke GWAS variants across different ancestry/ethnicity groups are lacking but important for prioritizing genetic variants for translational research and understanding population differences in stroke burden. In our secondary aim to replicate previous GWAS findings from European-ancestry populations, we found suggestive evidence of replication (P<0.05) for 4 loci. Interestingly, 4 of the 6 nominally significant SNPs in these loci were originally associated with cardioembolic stroke in European-ancestry populations. None were significant after Bonferroni correction; nonetheless, these trends suggest that variants in these loci may influence stroke risk independent of race/ethnicity. Some limitations of our study deserve mention. COMPASS case-control studies are limited to nonfatal and less severe strokes than longitudinal cohort studies, and are more likely to have potential selection bias. However, findings from analyses of the cohort studies were generally similar to the overall meta-analysis, though a rare intronic variant in CHD3, rs9899375, reached significance, P=5.2×10 −9 , in the cohort analyses only. The limited number of African American stroke samples in COMPASS restricts power to discover new loci and also to replicate previous associations of modest effect size. In addition, SNP imputation in admixed populations, such as African Americans, is challenging because of differing LD patterns and greater genetic diversity than in the standard reference panels. 32 Given the use of YRI/CEU HapMap II reference panels rather than African-American-specific panels for imputation, we may have slightly reduced power to detect associations (resulting in greater chance of false negatives), and reduced ability to localize stroke-associated variants in our population.
Total and ischemic stroke are heterogeneous outcomes. Recent GWAS of ischemic stroke have detected heterogeneity of associations across stroke subtypes. 7 Although the largest GWAS of stroke in African Americans, COMPASS still lacks adequate numbers to stratify by stroke subtype. In COMPASS studies with subtype information, ischemic stroke is predominant and lacunar (or small vessel) stroke is the most common ischemic stroke subtype, consistent with data indicating that intracranial atherosclerotic and lacunar (or small vessel) strokes predominate in African Americans. 8, 14 Furthermore, small vessel ischemic stroke incidence in African Americans is more than double that of US whites. 33 Thus, some of the observed differences in risk loci may reflect differences in distributions of major ischemic stroke subtypes across diverse populations. However, these differences offer an opportunity to identify shared or distinct risk factors and mechanisms for specific ischemic stroke subtypes across diverse populations, such as the nominally significant replication of cardioembolicassociated loci (PITX2 and ZFHX3) in COMPASS. Replication of African American GWAS SNPs in a European-ancestry at NIH Library on October 24, 2015 http://stroke.ahajournals.org/ Downloaded from population is not ideal because of differences in population LD, with African-ancestry populations having higher genetic diversity on average than European populations. 34 Yet, when we broadly interrogated the index SNP signals, we observed modest replication. Such data may help to localize the actual causal variants within GWAS signals.
Summary
Despite its limitations, our study presents results for a unique, lesser-studied population with a substantial stroke burden. Published stroke GWAS have identified only a handful of replicable associations, perhaps reflecting stroke phenotypic complexity and potential gene-by-environment influences in different populations. 35 Thus, genetic association studies in populations of diverse ancestry, such as this one, are critical to understanding the genetic basis of stroke, an increasingly important global disease.
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SUPPLEMENTAL MATERIAL
Meta-analysis of genome-wide association studies identifies genetic risk factors for stroke in African Americans
Supplemental Methods
Meta-Analysis
Additional checks for evidence of population stratification or structure were performed during the meta-analysis. The genomic inflation factors were estimated and determined to be 1.01 for the total stroke analysis, indicating minimal evidence of inflation of the test statistics due to stratification. As expected, the GC-adjusted test statistics were virtually identical to the unadjusted values (i.e. the top SNPs were consistent between both approaches), though pvalues increased slightly. In sensitivity analyses, we performed a meta-analysis of p-values using the weighted Z-score method implemented in METAL. This approach has reduced power compared with the effect size meta-analysis, 1 but does not necessarily require that effect estimates be measured on the same scale in all studies. Although the p-values from this analysis increased, in general, the ranking of SNPs was similar, with the exception of the GWAS-significant SNP, rs4471613. This SNP, which was only available in the cohort studies (ARIC, CHS, HABC and WHI) and attained GWAS-significance in the cohort only analysis, was no longer significant at the GWAS significance threshold in the p-value meta-analysis. Given the focus on discovery in this aim, interest in avoiding false negatives, and the subsequent replication effort, we present results from the effect estimate meta-analysis in the manuscript.
Study Descriptions
Atherosclerosis Risk in Communities (ARIC) Study
Population. The ARIC study is a prospective population-based study of atherosclerosis and clinical atherosclerotic diseases in 15,792 men and women, including 11,478 non-Hispanic white participants, drawn from 4 U.S. communities (Suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina, and Jackson, Mississippi). 2 In the first three communities, the sample reflects the demographic composition of the community. In Jackson, only black residents were enrolled. Ancestry was self-reported during an interview. Participants were handed a card and asked to tell the interviewer which best described his or her race. Choices offered were: White, Black, American Indian/ Alaskan Native, Asian/Pacific Islander, Other: specify. Over 99% identified as either white or black. Only self-identified blacks were included in this study. Participants were between age 45 and 64 years at their baseline examination in 1987-1989 when blood was drawn for DNA extraction and participants consented to genetic testing. 2 Only individuals free of stroke or TIA at baseline were included in the analysis.
Genotyping. Single-nucleotide polymorphisms (SNPs) were genotyped on the Affymetrix 6.0 chip and were imputed to ≈2.5 million SNPs based on a panel of cosmopolitan reference haplotypes from HapMap CEU and YRI (HapMap II CEU and YRI (build 35, release 21)). MACH v1.0.16 was used to perform genotype imputations and allele dosage information was summarized in the imputation results. SNPs were excluded if they had no chromosomal location, were monomorphic, had a call rate<95%, or had a Hardy-Weinberg equilibrium Pvalue<10-5. For each SNP, the ratio of the observed versus expected variance of the dosage served as the measure of imputation quality. SNPs with MAF<1% and imputation quality <0.3 were filtered out prior to meta-analysis. Individuals with and without genotype data did not significantly differ with regards to baseline CVD risk factors (not shown). We excluded individuals with a sex mismatch, those who were discordant for more than 5% of genotypes among 47 previously genotyped overlapping SNPs, persons who were 1st degree relatives, those who were outliers based on average identity by state or based on Eigenstrat clustering, or persons who had an incident subarachnoid hemorrhage.
Stroke Ascertainment. Hospitalized strokes that occurred by December 31, 2007 were included in the present study. During annual telephone contacts, trained interviewers asked each ARIC participant to list all hospitalizations during the past year. Hospital records for any hospitalizations identified were then obtained. In addition, all local hospitals annually provided lists of stroke discharges (International Classification of Diseases, Ninth Revision, Clinical Modification codes 430 to 438), which were scrutinized for ARIC participant discharges. Details on quality assurance for ascertainment and classification of stroke are described elsewhere. 3 Briefly, the stroke diagnosis was assigned according to criteria adapted from the National Survey of Stroke. 4 Strokes secondary to trauma, neoplasm, hematologic abnormality, infection, or vasculitis were excluded, and a focal deficit lasting <24 hours was not considered to be a stroke. Out-of-hospital stroke was not ascertained and validated; thus, these potential stroke events were not included. Strokes were classified into hemorrhagic stroke (subarachnoid and intracerebral hemorrhage) and ischemic stroke (thrombotic and embolic brain infarction). A stroke was classified as ischemic when a brain CT or MRI revealed acute infarction and showed no evidence of hemorrhage. All definite ischemic strokes were further classified as lacunar, nonlacunar thrombotic, or cardioembolic on the basis of the recorded neuroimaging results. For this analysis, the hemorrhagic strokes identified by ARIC were censored at the time of their occurrence.
Cardiovascular Health Study (CHS)
Population. CHS is a population-based cohort study of risk factors for coronary heart disease (CHD) and stroke in adults ≥ 65 years conducted across four field centers in the United States. 5 The original predominantly white cohort of 5,201 persons (4,964 whites) was recruited in 1989-1990 from a random sample of people on Medicare eligibility lists, and an additional 687 blacks were enrolled subsequently in 1992-93 for a total sample of 5,888. Race/ethnicity was determined by self-identification at interview. Only self-identified blacks were included in these analyses. DNA was extracted from blood samples drawn on all participants who consented to genetic testing at their baseline examination.
Genotyping. In 2007-2008, genotyping was performed at the General Clinical Research
Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV Duo®BeadChip system on participants who were free of CVD at baseline. Persons were also excluded for a subject-specific genotyping call rate ≤95%.
Stroke Ascertainment. Participants were examined annually from enrollment to 1999, and since then continue to be under surveillance for stroke. 6, 7 Since baseline, participants have also been contacted twice a year to identify potential cardiovascular events, including stroke. In addition, all hospitalizations were screened for potential stroke events. For suspected events, information was collected from the participant or next of kin, from medical records, and if needed, from the participant's physician. When available, CT scans, MRI scans and reports were reviewed centrally. At a consensus conference using all available information, vascular neurologists adjudicated all events and reached a final decision about the occurrence of stroke, stroke types and subtypes.
Genetics of Early Onset Stroke (GEOS)
Population. GEOS is a population-based case-control study designed to identify genes associated with early-onset ischemic stroke and to characterize interactions of identified stroke genes and/or SNPs with environmental risk factors. [8] [9] [10] Participants were recruited from the Stroke Ascertainment. Case participants were hospitalized with a first cerebral infarction identified by discharge surveillance from one of the 59 hospitals in the greater BaltimoreWashington area and direct referral from regional neurologists. The abstracted hospital records of cases were reviewed and adjudicated for ischemic stroke subtype by a pair of neurologists according to previously published procedures with disagreements resolved by a third neurologist. The ischemic stroke subtype classification system retains information on all probable and possible causes, and is reducible to the more widely used TOAST system that assigns each case to a single category. Control participants without a history of stroke were identified by random-digit dialing and were balanced to cases by age and region of residence in each recruitment periods.
Genotyping. Genomic DNA was isolated from a variety of sample types, including cell line, whole blood, mouth wash and buccal swab. Samples were genotyped at the Johns Hopkins Center for Inherited Disease Research (CIDR) using the Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San Diego, CA, USA). Assistance with data cleaning was provided by the GENEVA Coordinating Center (U01-HG-004446; PI Bruce S Weir). Individuals were excluded if they were unexpected duplicates, gender discrepancy and unexpected relatedness.
The Healthy Aging in Neighborhoods of Diversity across the Life Span Study (HANDLS)
In the absence of non-stroke control samples from the VISP, ISGS, and SWISS studies, controls from the Healthy Aging in Neighborhoods of Diversity across the Life Span study (HANDLS) study were used for the VISP and SWISS-ISGS case-control analyses (with no overlap across studies). Controls were sex and race/ethnicity-matched and randomly selected from all HANDLS participants not reporting history of stroke at baseline or reporting adjudicated stroke during follow-up.
Population. HANDLS is an interdisciplinary, community-based, prospective longitudinal epidemiologic study examining the influences of race and socioeconomic status (SES) on the development of age-related health disparities among socioeconomically diverse African Americans and whites in Baltimore, MD, USA. This study assesses physical parameters over a 20-year period while evaluating genetic, biologic, demographic, and psychosocial influences. HANDLS recruited 3,722 participants (2200 African Americans (59%) and 1522 whites (41%)) from Baltimore, MD.
Stroke Ascertainment. Stroke status at baseline was determined through self-report while incident strokes, other vascular events, and deaths were determined using medical records and clinic visits during follow-up.
Genotyping. Genotyping was focused on a subset of participants self-reporting as African American and was performed at the Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health. Genotype data (for up to 907,763 SNPs) were generated for 1,024 participants using either Illumina 1M and 1M duo arrays (n=709) ,or a combination of 550K, 370K, 510S and 240S to equate the million SNP level of coverage. Inclusion criteria for genetic data in HANDLS includes concordance between self-reported sex and sex estimated from X chromosome heterogeneity, > 95% call rate per participant (across all equivalent arrays), concordance between self-reported African ancestry and ancestry confirmed by analyses of genotyped SNPs, and no cryptic relatedness to any other samples at a level of proportional 5 sharing of genotypes > 15% (effectively excluding 1 st cousins and closer relatives from the set of probands used in analyses). In addition, SNPs included in the analysis were filtered for HWE pvalue > 1e-7, missing by haplotype p-values > 1e-7, minor allele frequency > 0.01, and call rate > 95%. Data analyses utilized the high-performance computational capabilities of the Biowulf Linux cluster at the NIH, Bethesda, Md. (http://biowulf.nih.gov). Stroke Ascertainment. Participants were questioned about any hospitalizations for stroke every 6 months. When an event was reported, hospital records were collected and verified by a Health ABC Disease Adjudicator at each site. Date and causes of death were taken from the death certificate. Follow-up time was defined as the time from the baseline visit until the first event date (for those who had an event) or was censored at the last contact date (for those who did not have any event or were lost to follow-up) or the day of death (for those who died of noncardiovascular causes).
Dynamics of
Genotyping. DNA samples were genotyped using the Illumina 1M array. Samples were excluded from the dataset for the reasons of sample failure, genotypic sex mismatch, and firstdegree relative of an included individual based on genotype data, low call rate <97% or HWE pvalue <10 -6 .
Ischemic Stroke Genetic Study (ISGS)
Population. ISGS is a multicenter inception cohort study. 12 Cases were recruited from inpatient stroke services at five United States academic medical centers.
Stroke Ascertainment. Cases are adult men and women over the age of 18 years diagnosed with first-ever ischemic stroke confirmed by a study neurologist on the basis of history, physical examination and CT or MR imaging of the brain. Cases had to be enrolled within 30 days of onset of stroke symptoms. Cases were excluded if they had: a mechanical aortic or mitral valve at the time of the index ischemic stroke, central nervous system vasculitis, or bacterial endocarditis. They were also excluded if they were known to have: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Fabry disease, homocystinuria, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), or sickle cell anemia. Diagnostic evaluation included: head CT (95%) or MRI (83%), electrocardiography (92%), cervical arterial imaging (86%), and echocardiography (74%). Medical records from all cases were centrally reviewed by a vascular neurology committee and assigned ischemic stroke subtype diagnoses according to TOAST criteria, 13 the Oxfordshire Community Stroke Project 14 , and the Baltimore-Washington Young Stroke Study 15 . DNA was donated to the NINDS DNA Repository (Coriell Institute, Camden, NJ) for eligible samples with appropriate written informed consent.
Genotyping. DNA samples were genotyped using the Illumina 610 array and data analyses were supported by the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (http://biowulf.nih.gov).
Siblings with Ischemic Stroke Study (SWISS)
Population. SWISS is a prospective multicenter affected sibling pair study of first-ever or recurrent ischemic stroke. 16 Subjects were recruited from 54 enrolling hospitals across the US and Canada. Samples were collected between 1999-2011. Ischemic stroke probands were enrolled at 66 US medical centers and 4 Canadian medical centers.
Stroke Ascertainment. All recruits were extensively clinically phenotyped and have imagingconfirmed ischemic stroke using either CT or MRI brain scans. Probands are adult men and women over the age of 18 years diagnosed with ischemic stroke confirmed by a study neurologist on the basis of history, physical examination and CT or MR imaging of the brain who also have a history of at least one living sibling with a history of stroke. Probands were excluded if 1) they had a mechanical aortic or mitral valve at the time of the index ischemic stroke, central nervous system vasculitis, or bacterial endocarditis or 2) were known to have cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Fabry disease, homocystinuria, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), or sickle cell anemia. Siblings were enrolled using probandinitiated contact 17 or direct contact when permitted by Institutional Review Boards. Concordant siblings had their diagnosis of ischemic stroke confirmed by review of medical records by a central vascular neurology committee. Concordant siblings had the same eligibility criteria as probands. Subtype diagnoses were assigned to the index strokes of probands and concordant siblings according to TOAST criteria. Discordant siblings of the proband were confirmed to be stroke-free using the Questionnaire for Verifying Stroke-free Status. 18 Genotyping. DNA samples were genotyped using the Illumina 660 array and data analyses were supported by the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (http://biowulf.nih.gov).
The Vitamin Intervention for Stroke Prevention (VISP) Study
Population. VISP is a multi-center, double-blind, randomized, controlled clinical trial that enrolled patients aged 35 or older with homocysteine levels above the 25th percentile at screening and a non-disabling cerebral infarction (NDCI) within 120 days of randomization. 19, 20 The trial was designed to determine if daily intake of a multivitamin tablet with high dose folic acid, vitamin B6 and vitamin B12 reduced recurrent cerebral infarction (1° endpoint), and nonfatal myocardial infarction (MI) or mortality (2° endpoints). Subjects were randomly assigned to receive daily doses of the high-dose formulation (n=1,827), containing 25mg pyridoxine (B6), 0.4mg cobalamin (B12), and 2.5mg folic acid; or the low-dose formulation (n=1,853), containing 200μg pyridoxine, 6μg cobalamin and 20μg folic acid. Enrollment in VISP began in August 1997, and was completed in December 2001, with 3,680 participants enrolled, from 55 clinic sites across the US and Canada and one site in Scotland. A subset of VISP participants gave consent and were included in the GWAS component of VISP, supported by the National Human Genome Research Institute (NHGRI), Grant U01 HG005160, as part of the Genomics and Randomized Trials Network (GARNET) Stroke Ascertainment. NDCI was defined as an ischemic brain infarction not due to embolism from a cardiac source, characterized by the sudden onset of a neurological deficit. The deficit must have persisted for at least 24 hours, or if not, an infarction in the part of the brain corresponding to the symptoms must have been demonstrated by CT or MRI imaging.
Genotyping. Samples were genotyped at the Center for Inherited Disease Research using the Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San Diego, CA, USA). Population. The goal of the WHI is to investigate the etiology and prevention of chronic disease in post-menopausal women. 21 WHI recruited approximately 161, 0000 postmenopausal women 50-79 years of age from 40 clinical centers in the US between 1993 and 1998. WHI consists of an observational study (OS), and clinical trials (CT) of postmenopausal hormone therapy (estrogen alone or estrogen plus progestin), a calcium and vitamin D supplement trial, and a dietary modification trial. A subset of 8,515 AA women who provided consent for DNA analysis were randomly selected for genome-wide genotyping as part of the SNP Health Association Resource (SHARe) project. 22 Study protocols and consent forms were approved by the institutional review boards for all participating institutions.
Stroke Ascertainment. All incident strokes, other vascular events, and deaths were identified through self-report at annual (OS) and semi-annual (CT) participant contacts, and through thirdparty reports by family members and proxies. Medical records were obtained for potential strokes, and adjudication was performed by trained physician adjudicators who assigned a diagnosis. Stroke diagnosis requiring and/or occurring during hospitalization was based on rapid onset of a neurological deficit attributable to an obstruction or rupture of an arterial vessel system. The deficit was not known to be secondary to brain trauma, tumor, infection or other cause and must have lasted more than 24 hours unless death supervened or a lesion compatible with acute stroke was evident on computed tomography or magnetic resonance imaging scan. 23 Strokes were classified as ischemic, hemorrhagic or unknown/missing. Ischemic stroke subtypes were further classified using Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 13 For analyses, strokes subtypes judged as 'probable' or 'possible' were combined.
Genotyping. Genetic data were obtained from genome-wide scans using the Genome-wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, www.affymetrix.com) of 909,622 single nucleotide polymorphisms (SNPs). Genotyping quality control included examination of concordance rates for blinded and un-blinded duplicates. Approximately 1% of SNPs failed genotyping and SNPs with call rates < 95% or concordance rates <98%, or minor allele frequency <1% were excluded. In addition to the genotyping, SNPs were imputed using MACH software 24 and the HapMapII CEU+YRI as reference populations. Out of 2,203,609 imputed SNPs, 2,192,719 SNPs had Rsq>0.3, the recommended cutoff for HapMap-based imputation, and were included in these analyses. Genotyping failed in 99 samples. Additional participants were excluded based on low call rates <95%, and sex or race/ethnicity discrepancy. First or second degree relatedness was assessed as described in Thornton and McPeek. 25 For the related individuals, the first or second degree relative with the highest call rate was retained in analyses and other family members were excluded. A principal-component (PC) analysis of all samples was performed using EIGENSTRAT 26 . The first 10 PCs were calculated for each individual and evaluated for their contribution to ancestral variation. Because most of the ancestral variation was explained by the first 4 PCs, only these were included as covariates in the analyses. We calculated lambda (λ), an indicator of over-dispersion due to potential population stratification by dividing the mean of the test statistics by the mean of the expected values from a Chi-squared distribution with 1 degree of freedom. Using λ, we investigated correction of p-values using genomic control to account for potential residual confounding by genetic ancestry. 27, 28 AA women passing the above genotyping quality control criteria, with follow-up data, and without a history of stroke at baseline are included in these analyses.
METASTROKE Replication Cohort
To determine if stroke genetic variants identified in the COMPASS study would replicate in populations of European ancestry, we utilized the discovery sample population from the METASTROKE consortium. 29 The METASTROKE population consists of 15 cohorts with ischemic stroke cases and controls of European ancestry from Europe, North America, and Australia. Each case-control population was genotyped using either Affymetrix (Santa Clara, CA, USA) or Illumina (San Diego, CA, USA) GWAS SNP arrays. Genotyped data were imputed using the HapMap II reference populations. Logistic regression tests of association were performed for each individual case-control population, followed a meta-analysis using a fixedeffects inverse-variance weighted model as implemented in METAL. CAF=coded allele frequency; AA=African Americans from COMPASS; CEU=HapMap II CEU population; SE=standard error *coded allele/non-coded allele †effect of each additional allele on risk of stroke (meta-analysis result) 
9
Supplemental
11
Supplemental
Supplemental Methods
Meta-Analysis
Additional checks for evidence of population stratification or structure were performed during the meta-analysis. The genomic inflation factors were estimated and determined to be 1.01 for the total stroke analysis, indicating minimal evidence of inflation of the test statistics due to stratification. As expected, the GC-adjusted test statistics were virtually identical to the unadjusted values (i.e. the top SNPs were consistent between both approaches), though pvalues increased slightly.
In sensitivity analyses, we performed a meta-analysis of p-values using the weighted Z-score method implemented in METAL. This approach has reduced power compared with the effect size meta-analysis, 1 but does not necessarily require that effect estimates be measured on the same scale in all studies. Although the p-values from this analysis increased, in general, the ranking of SNPs was similar, with the exception of the GWAS-significant SNP, rs4471613. This SNP, which was only available in the cohort studies (ARIC, CHS, HABC and WHI) and attained GWAS-significance in the cohort only analysis, was no longer significant at the GWAS significance threshold in the p-value meta-analysis. Given the focus on discovery in this aim, interest in avoiding false negatives, and the subsequent replication effort, we present results from the effect estimate meta-analysis in the manuscript.
Study Descriptions
Atherosclerosis Risk in Communities (ARIC) Study
Cardiovascular Health Study (CHS)
Genotyping. In 2007-2008, genotyping was performed at the General Clinical Research
Genetics of Early Onset Stroke (GEOS)
The Healthy Aging in Neighborhoods of Diversity across the Life Span Study (HANDLS)
Dynamics of
Ischemic Stroke Genetic Study (ISGS)
Siblings with Ischemic Stroke Study (SWISS)
The Vitamin Intervention for Stroke Prevention (VISP) Study
Genotyping. Genetic data were obtained from genome-wide scans using the Genome-wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, www.affymetrix.com) of 909,622 single nucleotide polymorphisms (SNPs). Genotyping quality control included examination of concordance rates for blinded and un-blinded duplicates. Approximately 1% of SNPs failed genotyping and SNPs with call rates < 95% or concordance rates <98%, or minor allele frequency <1% were excluded. In addition to the genotyping, SNPs were imputed using MACH software 24 and the HapMapII CEU+YRI as reference populations. Out of 2,203,609 imputed SNPs, 2,192,719 SNPs had Rsq>0.3, the recommended cutoff for HapMap-based imputation, and were included in these analyses. Genotyping failed in 99 samples. Additional participants were excluded based on low call rates <95%, and sex or race/ethnicity discrepancy. First or second degree relatedness was assessed as described in Thornton and McPeek. 25 For the related individuals, the first or second degree relative with the highest call rate was retained in analyses and other family members were excluded. A principal-component (PC) analysis of all samples was performed using EIGENSTRAT 26 . The first 10 PCs were calculated for each individual and evaluated for their contribution to ancestral variation. Because most of the ancestral variation was explained by the first 4 PCs, only these were included as covariates in the analyses. We calculated lambda (λ), an indicator of over-dispersion due to potential population stratification by dividing the mean of the test statistics by the mean of the expected values from a Chi-squared distribution with 1 degree of freedom. Using λ, we investigated correction of p-values using genomic control to account for potential residual confounding by genetic ancestry. 27, 28 AA women passing the above genotyping quality control criteria, with follow-up data, and without a history of stroke at baseline are included in these analyses. 
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